RELMADA DEPRESSION STUDY
What is this study investigating?
To evaluate the therapeutic efficacy of REL-1017 (Esmethadone) as an adjunctive treatment compared to placebo with antidepressant therapy.
What is Esmethadone?: Esmethadone is an NMDAR blocker, that is taken in the form of an oral pill. Blocking hyperactive NMDAR channels represents a novel approach to treating depression with a mechanism that is different from the classes of currently approved drugs. Through early clinical trials, we have seen this medication has a low affinity for respiratory depression and addiction.
Overview: This is a 28-day long study with a 2 week follow up phase. 7 in-office visits are required for the first 4 weeks, and 4 in-office visits are required for the 2-week follow up phase.
You May Qualify If:
Qualified candidates may be compensated $50 per visit.